Meta AnalysisID 6804
芪苈强心胶囊联合西药治疗慢性心力衰竭的疗效与安全性：系统评价与Meta分析概览
CRD42023413733
This overview is designed to assess the efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6804
- Evidence Id
- 15362
- Core Evidence Id
- 15362
- Source Meta Analysis Id
- 6786
- Herb2 Meta Analysis Id
- HBMA006786
- Crd Id
- CRD42023413733
- Title
- Efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure : An overview of systematic reviews and meta-analyses
- Review Question
- This overview is designed to assess the efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure.
- Study Type Included
- Meta-analyses and systematic reviews of Qili Qiangxin capsules combined with western medicine for the treatment of chronic heart failure.
- Condition Being Studied
- Efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure
- Participant
- Patients with a definite diagnosis of chronic heart failure (according to the diagnostic criteria of internationally recognized guidelines).
- Animal
- Human Disease Modelled
- Intervention
- Qili Qiangxin Capsule combined with conventional Western medical treatment.
- Comparator Control
- Western medical treatment alone.
- Main Outcome
- Methodological quality, level of evidence and quality of reporting (using AMSTAR-2, GRADE and PRISMA tools, respectively) Measures of effect 1. Included studies will be rated as high, moderate, low, or very low quality using the AMSTAR2 scale. 2. The outcome indicators of the included literature will be assessed using GRADE, and the outcome indicators will be assessed as individual evidence based on risk of bias, inconsistency, indirectness, imprecision, and publication bias for each systematically assessed outcome indicator with 5 factors. 3.Each study will be assessed as "yes", "no", and "partially yes" by PRISMA tool.
- Outcome Measure
- Additional Outcome
- Left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), N-terminal Pro B-type natriuretic peptide (NT-proBNP), 6-minute walk test (6MWT), NYHA cardiac function class, adverse events, etc.
- Study Method
- Systematic review
- Keyword
- Chronic Disease; Drugs, Chinese Herbal; Heart Failure; Humans; Medicine; Systematic Reviews as Topic; qiangxin
- Contact
- Chunxiao, Ju [email protected]
- Organisational Affiliation
- Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine http://www.xyhospital.com
- Funding Source
- National Natural Science Foundation of China Grant number(s) State the funder, grant or award number and the date of award No.8220154617
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-04-09
- Registration Date
- 2023-04-20
- Anticipated Start Date
- 2023-04-15
- Anticipated Completion Date
- 2023-06-15
- Title Cn
- 芪苈强心胶囊联合西药治疗慢性心力衰竭的疗效与安全性：系统评价与Meta分析概览
- Title En
- Efficacy and safety of Qili Qiangxin Capsule combined with western medicine in the treatment of chronic heart failure : An overview of systematic reviews and meta-analyses
- Bilingual Status
- complete